دورية أكاديمية
Real-world data on treatment outcomes in EGFR-mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines
| العنوان: | Real-world data on treatment outcomes in EGFR-mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines |
|---|---|
| المؤلفون: | Dal Maso, A, Lorenzi, M, Ferro, A, Pilotto, S, Cecere, F, Follador, A, Polo, V, Del Conte, A, Sartori, G, Giavarra, M, Scattolin, D, Indraccolo, S, Frega, S, De Maglio, G, Menis, J, Bonanno, L, Calabrese, F, Guarneri, V, Conte, P, Pasello, G |
| المساهمون: | Dal Maso, A, Lorenzi, M, Ferro, A, Pilotto, S, Cecere, F, Follador, A, Polo, V, Del Conte, A, Sartori, G, Giavarra, M, Scattolin, D, Indraccolo, S, Frega, S, De Maglio, G, Menis, J, Bonanno, L, Calabrese, F, Guarneri, V, Conte, P, Pasello, G |
| بيانات النشر: | FUTURE MEDICINE LTD |
| سنة النشر: | 2021 |
| المجموعة: | Padua Research Archive (IRIS - Università degli Studi di Padova) |
| مصطلحات موضوعية: | acquired resistance, EGFR T790M mutation, epidermal growth factor receptor, non-small-cell lung cancer, tyrosine kinase inhibitors |
| الوصف: | Aims: This study describes real-world outcomes of pretreated EGFR T790M-positive (T790M(+)) advanced non-small-cell lung cancer patients progressing after first- or second-generation tyrosine kinase inhibitors and receiving osimertinib, compared with T790M-negative (T790M(-)) patients. We have also described progression patterns and treatment sequences. Patients & methods: This is a retrospective multicenter Italian observational study including consecutive Caucasian patients referred between 2014 and 2018. Results: 167 patients were included. Median progression-free survival was 9.8 months (95% CI: 8.3-13.3) for T790M(+) and 6.0 months (95% CI: 4.9-7.2) for T790M(-) patients, respectively. Median overall survival was 20.7 months (95% CI: 18.9-28.4) for T790M(+) and 10.6 months (95% CI: 8.6-23.6) for T790M(-) patients, respectively. The T790M mutation correlated with absence of new sites of disease. After progression, most T790M(+) patients continued osimertinib, whereas most T790M(-) patients received a different treatment line. Conclusion: Better outcomes were shown in patients receiving osimertinib. A more limited progression pattern for T790M(+) was suggested.Lay abstractOsimertinib is an oral drug that inhibits the growth of non-small-cell lung cancer (NSCLC) tumors with a specific mutation in EGFR. Osimertinib is given to patients with advanced EGFR-mutant NSCLC as initial therapy or after the failure of prior first- or second-generation tyrosine kinase inhibitors in patients who develop the EGFR T790M resistance mutation. Real-world data about the efficacy of EGFR-mutant NSCLC patients receiving osimertinib are needed to confirm the findings of large randomized clinical trials. Most real-world studies have investigated outcomes in Asian populations. This study aims to describe outcomes in EGFR T790M-positive patients receiving osimertinib after the failure of first- or second-generation tyrosine kinase inhibitors, compared with T790M-negative patients receiving a systemic treatment, in a Caucasian ... |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | ELETTRONICO |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/33988036; info:eu-repo/semantics/altIdentifier/wos/WOS:000650051900001; journal:FUTURE ONCOLOGY; http://hdl.handle.net/11577/3391531Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85107904377 |
| DOI: | 10.2217/fon-2021-0356 |
| الإتاحة: | https://doi.org/10.2217/fon-2021-0356Test http://hdl.handle.net/11577/3391531Test |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.6ACA6FBB |
| قاعدة البيانات: | BASE |
| DOI: | 10.2217/fon-2021-0356 |
|---|